Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
37.26
+1.04 (2.87%)
At close: Aug 1, 2025, 4:00 PM
37.47
+0.21 (0.56%)
After-hours: Aug 1, 2025, 4:29 PM EDT
Exelixis Revenue
Exelixis had revenue of $568.26M in the quarter ending June 30, 2025, a decrease of -10.82%. This brings the company's revenue in the last twelve months to $2.23B, up 10.73% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+10.73%
P/S Ratio
4.68
Revenue / Employee
$1,944,207
Employees
1,147
Market Cap
10.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EXEL News
- 2 days ago - Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards - Seeking Alpha
- 4 days ago - Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans - Benzinga
- 4 days ago - Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 8 days ago - Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 19 days ago - Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - Business Wire
- 5 weeks ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 5 weeks ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga